Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dropping Rx Lines Would Be Costly Distribution Negotiation Tactic, ABC Says

Executive Summary

AmerisourceBergen does not see dropping distribution of certain drug product lines as a viable option for the wholesale industry in its effort to move manufacturers to fee-for-service contracts

You may also be interested in...



“Big Three” Wholesalers Will Rotate HDMA Chairmanship

The heads of the three largest members of the Healthcare Distribution Management Association will assume a rotating chairmanship of HDMA

“Big Three” Wholesalers Will Rotate HDMA Chairmanship

The heads of the three largest members of the Healthcare Distribution Management Association will assume a rotating chairmanship of HDMA

Cardinal Fee-For-Service Ultimatum Is Serious, CEO Says

Cardinal is ready to make good on its threat to cut off drug distribution services for products not covered under a fee-for-service distribution agreement by the end of March, CEO Bob Walter said

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel